Literature DB >> 26261733

Primary biliary cirrhosis: From bench to bedside.

Elias Kouroumalis1, George Notas1.   

Abstract

Primary biliary cirrhosis (PBC) is a chronic non-suppurative destructive intrahepatic cholangitis leading to cirrhosis after a protractive non cirrhotic stage. The etiology and pathogenesis are largely unknown and autoimmne mechanisms have been implicated to explain the pathological lesions. Many epitopes and autoantigens have been reported as crucial in the pathophysiology of the disease and T and B cells abnormalities have been described, the exact pathways leading to the destruction of small intrahepatic ductules are mostly speculative. In this review we examined the various epidemiologal and geoepidemiological data as well as the complex pathogenetic aspects of this disease, focusing on recent in vivo and in vitro studies in this field. Initiation and progression of PBC is believed to be a multifactorial process with strong infuences from the patient's genetic background and by various environmental factors. The role of innate and adaptive immunity, including cytokines, chemokines, macrophages and the involvement of apoptosis and reactive oxygen species are outlined in detailed. The current pathogenetic aspects are presented and a novel pathogenetic theory unifying the accumulated clinical information with in vitro and in vivo data is formulated. A review of clinical manifestations and immunological and pathological diagnosis was presented. Treatment modalities, including the multiple mechanisms of action of ursodeoxycholate were finally discussed.

Entities:  

Keywords:  Adaptive immunity; Chemokines; Cytokines; Innate immunity; Macrophages; Primary biliary cirrhosis; Ursodeoxycholate

Year:  2015        PMID: 26261733      PMCID: PMC4526840          DOI: 10.4292/wjgpt.v6.i3.32

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  350 in total

1.  Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.

Authors:  Hiroto Kita; Shuji Matsumura; Xiao-Song He; Aftab A Ansari; Zhe-Xiong Lian; Judy Van de Water; Ross L Coppel; Marshall M Kaplan; M Eric Gershwin
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

Authors:  Masanobu Tsuda; Yuki Moritoki; Zhe-Xiong Lian; Weici Zhang; Katsunori Yoshida; Kanji Wakabayashi; Guo-Xiang Yang; Toshio Nakatani; John Vierling; Keith Lindor; M Eric Gershwin; Christopher L Bowlus
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

Review 3.  Turning NF-kappaB and IRFs on and off in DC.

Authors:  Tsuneyasu Kaisho; Takashi Tanaka
Journal:  Trends Immunol       Date:  2008-06-03       Impact factor: 16.687

4.  Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.

Authors:  J Goulis; G Leandro; A K Burroughs
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

5.  The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.

Authors:  E M M Kuiper; B E Hansen; W Lesterhuis; R J Robijn; J C Thijs; L G J B Engels; G H Koek; M N Aparicio; M J Kerbert-Dreteler; H R van Buuren
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-01       Impact factor: 2.947

6.  Assessment of biliary bicarbonate secretion in humans by positron emission tomography.

Authors:  J Prieto; N García; J M Martí-Climent; I Peñuelas; J A Richter; J F Medina
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

7.  Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids.

Authors:  R J Sokol; M S Straka; R Dahl; M W Devereaux; B Yerushalmi; E Gumpricht; N Elkins; G Everson
Journal:  Pediatr Res       Date:  2001-04       Impact factor: 3.756

8.  Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

Authors:  R Poupon; Y Chrétien; R E Poupon; F Ballet; Y Calmus; F Darnis
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

9.  Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver.

Authors:  Andrew P Holt; Emma L Haughton; Patricia F Lalor; Andrew Filer; Christopher D Buckley; David H Adams
Journal:  Gastroenterology       Date:  2008-10-15       Impact factor: 22.682

10.  Geographic clusters of primary biliary cirrhosis.

Authors:  Saif Abu-Mouch; Carlo Selmi; Gordon D Benson; Thomas P Kenny; Pietro Invernizzi; Massimo Zuin; Mauro Podda; Lorenzo Rossaro; M Eric Gershwin
Journal:  Clin Dev Immunol       Date:  2003 Jun-Dec
View more
  2 in total

1.  Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report.

Authors:  Sailaja Kamaraju; Jill Depke; Janice Povletich; Adam Currey; Elizabeth Weil
Journal:  Case Rep Oncol       Date:  2016-11-08

Review 2.  Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis.

Authors:  Aleksandar Arsenijevic; C Randall Harrell; Crissy Fellabaum; Vladislav Volarevic
Journal:  Anal Cell Pathol (Amst)       Date:  2017-12-19       Impact factor: 2.916

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.